Belgium Pharmaceuticals and Healthcare Report Q3 2014

  • June 2014
  • -
  • Business Monitor International
  • -
  • 125 pages

Includes 3 FREE quarterly updates
Belgium continues to attract the attention of multinational firms as a European hub for clinical trials, new
drug development and niche research. However, a highly developed pharmaceutical manufacturing industry
is increasingly threatened by cheaper suppliers from Eastern Europe and Asia. Even though per
capita spending on pharmaceuticals is relatively high, it is subjected to continual downward pressure, which
translates into growth opportunities for generic drugs. The increased uptake of generic drugs will reduce
costs for governments, out-of-pocket payers and insurance companies, which is increasingly important as
developed states reform their healthcare systems over the medium term. Prescribers' brand loyalty, pay-todelay
deals, the near-universal unpopularity of commodity generics and a lack of perfect competition in the
pharmaceutical sector, however, constitute key impediments to further generic expansion.




Headline Expenditure Projections


- Pharmaceuticals: EUR5.79bn (USD7.64bn) in 2013 to EUR5.68bn (USD7.61bn) in 2014; -2.0% in
local currency terms and -0.5% in US dollar terms. Local currency forecast slightly lower than in
Q214.
- Healthcare: EUR41.79bn (USD55.17bn) in 2013 to EUR42.76bn (USD57.29bn) in 2014; +2.3% in local
currency terms and 3.8% in US dollar terms. Local currency forecast higher than in Q214.

Table Of Contents

Belgium Pharmaceuticals and Healthcare Report Q3 2014
BMI Industry View ... 7
SWOT .. 10
Political . 12
Economic ... 13
Industry Forecast .. 14
Pharmaceutical Market Forecast 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belgium 2010-2018) 15
Healthcare Market Forecast .. 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018) . 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018) . . 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018) . . 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018) . 21
Patented Drug Market Forecast . 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018) . . 23
Generic Drug Market Forecast .. 24
Table: Generic Companies By Market Share, 2010 . 26
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018) . . 28
OTC Medicine Market Forecast . 29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belgium 2010-2018) . 30
Pharmaceutical Trade Forecast . 31
Table: Pharmaceutical Trade Data And Forecasts (Belgium 2012-2018) . . 33
Table: Pharmaceutical Trade Data And Forecasts local currency (Belgium 2012-2018) . 33
Other Healthcare Data . 34
Key Risks To BMI's Forecast Scenario . 35
Macroeconomic Forecasts ... 36
Economic Analysis ... 36
Table: Belgium - Economic Activity . . 39
Industry Risk Reward Ratings .. 40
Western Europe Risk/Reward Ratings .. 40
Belgium Risk/Reward Ratings 45
Rewards ... 45
Risks 45
Market Overview ... 47
Industry Trends And Developments 49
Epidemiology 49
Public Health Developments 50
Healthcare Sector .. 51
Healthcare Insurance .. 52
Healthcare Financing . 53
Medical Tourism 54
Research And Development .. 55
Table: RandD Investment By Chemical and Life Science Industries, 2005-2010 . . 55
Clinical Trials ... 59
Regulatory Development .. 61
Pharmaceutical Advertising . 62
Regulatory Developments 62
Intellectual Property Issues .. 63
Pricing Regime .. 64
Reimbursement Regime ... 65
Table: Reimbursements By Category, 2009 67
Table: Price Build-Up For OTC Medicines 69
Competitive Landscape 70
Pharmaceutical Sector 70
Recent Company Developments 71
Pharmaceutical Distribution 74
Table: Members Of AnGR, 2011 74
Pharmaceutical Retail Sector ... 75
Table: Members Of OPHACO, 2011 . 76
Company Profile 78
UCB Pharma .. 78
Solvay (Abbott) ... 86
Janssen Pharmaceutica 89
Omega Pharma ... 92
Galapagos (GSK) 96
GlaxoSmithKline ... 102
Pfizer .. 105
Novartis ... 108
Sanofi .. 110
Merck and Co .. 113
Demographic Forecast ... 115
Table: Belgium's Population By Age Group, 1990-2020 ('000) 116
Table: Belgium's Population By Age Group, 1990-2020 (% of total) 117
Table: Belgium's Key Population Ratios, 1990-2020 . 118
Table: Belgium's Rural And Urban Population, 1990-2020 118
Glossary ... 119
Methodology 121
Pharmaceutical Expenditure Forecast Model 121
Healthcare Expenditure Forecast Model ... 121
Notes On Methodology .. 122
Risk/Reward Ratings Methodology .. 123
Ratings Overview . 124
Table: Pharmaceutical Risk/Reward Ratings Indicators . 124
Indicator Weightings 125

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with ...

OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • January 2015
  • by Global Data

OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018 Summary GlobalData estimates that the 2013 sales for the Cushing’s syndrome (CS) therapeutic market was approximately ...

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered ...


Download Unlimited Documents from Trusted Public Sources

Cancer Drug Market in Mexico

  • April 2015
    2 pages
  • Cancer Drug  

    Public Health I...  

    Pharmaceutical  

  • Mexico  

    Brazil  

    North America  

View report >

Pathology Description in the US

  • April 2015
    7 pages
  • Cancer  

    Cancer Drug  

  • United States  

    World  

    North America  

View report >

Opioid Industry in the US

  • April 2015
    13 pages
  • Opioid  

  • United States  

View report >

Related Market Segments :

Pharmaceutical
Drug
Medicine
Healthcare

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.